

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): May 29, 2007

**McKesson Corporation**

(Exact name of registrant as specified in its charter)

<u>Delaware</u> (State or other jurisdiction of incorporation)	<u>001-13252</u> (Commission File Number)	<u>94-3207296</u> (I.R.S. Employer Identification No.)
<u>McKesson Plaza, One Post Street, San Francisco, California</u> (Address of principal executive offices)		<u>94104</u> (Zip Code)

Registrant's telephone number, including area code: 415-983-8300

Not Applicable

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
-

---

## Item 8.01 Other Events

McKesson Corporation (the “Company”) today is providing to investors quarterly Recast Condensed Consolidated Income Information by Business Segment for Fiscal 2006 and Fiscal 2007. As described in our Annual Report on Form 10-K for the fiscal year ended March 31, 2007 filed on May 9, 2007, beginning with the first quarter of fiscal 2008, we will report our operations in two segments: McKesson Distribution Solutions and McKesson Technology Solutions. This change resulted from a realignment of our businesses to better coordinate our operations with the needs of our customers. The factors for determining the reportable segments included the manner in which management evaluated the performance of the Company combined with the nature of the individual business activities. In accordance with Statement of Financial Accounting Standards No. 131, “Disclosures about Segments of an Enterprise and Related Information,” all prior period segment information has been reclassified to conform to this new presentation. Additional information regarding our new segments is as follows:

The McKesson Distribution Solutions segment distributes ethical and proprietary drugs, medical-surgical supplies and equipment, and health and beauty care products throughout North America. We have combined two of our former segments known as our Pharmaceutical Solutions and Medical-Surgical Solutions segments into this new segment which reflects the increasing synergies the Company is seeking through combined back office activities and best-practice process improvements. This segment also provides specialty pharmaceutical solutions for biotech and pharmaceutical manufacturers, sells pharmacy software, and provides consulting, outsourcing and other services. This segment includes a 49% interest in Nadro, S.A. de C.V., the leading pharmaceutical distributor in Mexico and a 39% interest in Parata Systems, LLC, which sells automated pharmaceutical dispensing systems to retail pharmacies.

The McKesson Technology Solutions segment (formerly known as our Provider Technologies segment) delivers enterprise-wide patient care, clinical, financial, supply chain, and strategic management software solutions, pharmacy automation for hospitals, as well as connectivity, outsourcing and other services, to healthcare organizations throughout North America, the United Kingdom and other European countries. The segment’s customers include hospitals, physicians, homecare providers, retail pharmacies and payors. We have added our Payor group of businesses, which includes our InterQual and clinical auditing and compliance software businesses and our disease and medical management programs to this segment. The change to move our Payor group to this segment from our former Pharmaceutical Solutions segment reflects our decision to more closely align this business with the strategy we are pursuing in our Technology Solutions segment to create value by promoting connectivity, economic alignment and transparency of information between payors and providers.

Revenues for our Technology Solutions segment are classified in one of three categories: software and software systems, services and hardware. Software and software systems revenues primarily include revenues from licensing our software and software systems, including the segment’s clinical auditing and compliance and InterQual businesses. Service revenues primarily include fees associated with installing our software and software systems, as well as revenues associated with software maintenance and support, remote processing, disease and medical management, and other outsourcing and professional services.

## Item 9.01 Financial Statements and Exhibits

### (d) Exhibits

99.1 Recast Condensed Consolidated Income Information by Business Segment for Fiscal 2006 and Fiscal 2007.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: May 29, 2007

MCKESSON CORPORATION

/s/ Jeffrey C. Campbell

**Jeffrey C. Campbell**

*Executive Vice President, Chief Financial  
Officer and Principal Financial Officer*

---

**EXHIBIT INDEX**

<b><u>Exhibit Number</u></b>	<b><u>Description of Document</u></b>
99	Recast Condensed Consolidated Income Information by Business Segment for Fiscal 2006 and Fiscal 2007.

**McKESON CORPORATION**  
**RECAST CONDENSED CONSOLIDATED INCOME INFORMATION BY BUSINESS SEGMENT**  
(unaudited)  
(in millions)

	FY06					FY07				
	Q1	Q2	Q3	Q4	FY	Q1	Q2	Q3	Q4	FY
<b>REVENUES</b>										
<b>Distribution Solutions</b>										
U.S. Pharmaceutical direct distribution and services	\$12,222	\$12,649	\$13,169	\$13,690	\$51,730	\$13,403	\$13,147	\$13,414	\$14,163	\$54,127
U.S. Pharmaceutical sales to customers' warehouses	6,078	6,199	6,522	6,663	25,462	7,094	6,483	6,836	7,142	27,555
Subtotal	18,300	18,848	19,691	20,353	77,192	20,497	19,630	20,250	21,305	81,682
Canadian pharmaceutical distribution and services	1,487	1,467	1,531	1,425	5,910	1,750	1,651	1,685	1,606	6,692
Medical-Surgical distribution and services	477	508	544	508	2,037	577	580	632	575	2,364
Total Distribution Solutions	20,264	20,823	21,766	22,286	85,139	22,824	21,861	22,567	23,486	90,738
<b>Technology Solutions</b>										
Software & software systems	103	109	133	151	496	124	141	139	159	563
Services	299	286	299	313	1,197	326	348	367	469	1,510
Hardware	34	35	42	40	151	41	36	38	51	166
Total Technology Solutions	436	430	474	504	1,844	491	525	544	679	2,239
Revenues	\$20,700	\$21,253	\$22,240	\$22,790	\$86,983	\$23,315	\$22,386	\$23,111	\$24,165	\$92,977
<b>GROSS PROFIT</b>										
Distribution Solutions	\$ 681	\$ 666	\$ 744	\$ 792	\$ 2,883	\$ 770	\$ 769	\$ 790	\$ 923	\$ 3,252
Technology Solutions	215	202	230	247	894	226	255	271	328	1,080
Gross profit	\$ 896	\$ 868	\$ 974	\$ 1,039	\$ 3,777	\$ 996	\$ 1,024	\$ 1,061	\$ 1,251	\$ 4,332
<b>OPERATING EXPENSES</b>										
Distribution Solutions	\$ 387	\$ 414	\$ 432	\$ 440	\$ 1,673	\$ 470	\$ 448	\$ 462	\$ 516	\$ 1,896
Technology Solutions	165	170	185	200	720	192	206	210	276	884
Corporate	38	58	48	69	213	62	70	71	91	294
Subtotal	590	642	665	709	2,606	724	724	743	883	3,074
Securities Litigation charge (credit), net	52	—	1	(8)	45	—	(6)	—	—	(6)
Operating expenses	\$ 642	\$ 642	\$ 666	\$ 701	\$ 2,651	\$ 724	\$ 718	\$ 743	\$ 883	\$ 3,068
<b>OTHER INCOME, NET</b>										

Distribution Solutions	\$ 8	\$ 9	\$ 10	\$ 13	\$ 40	\$ 13	\$ 7	\$ 12	\$ 7	\$ 39
Technology Solutions	2	5	2	4	13	2	3	2	3	10
Corporate	17	21	23	25	86	20	22	25	16	83
Other income, net	<u>\$ 27</u>	<u>\$ 35</u>	<u>\$ 35</u>	<u>\$ 42</u>	<u>\$ 139</u>	<u>\$ 35</u>	<u>\$ 32</u>	<u>\$ 39</u>	<u>\$ 26</u>	<u>\$ 132</u>

#### OPERATING PROFIT

Distribution Solutions	\$ 302	\$ 261	\$ 322	\$ 365	\$ 1,250	\$ 313	\$ 328	\$ 340	\$ 414	\$ 1,395
Technology Solutions	52	37	47	51	187	36	52	63	55	206
Operating profit	354	298	369	416	1,437	349	380	403	469	1,601
Corporate	(21)	(37)	(25)	(44)	(127)	(42)	(48)	(46)	(75)	(211)
Securities Litigation (charge) credit, net	(52)	—	(1)	8	(45)	—	6	—	—	6
Income from continuing operations before interest expense and income taxes	<u>\$ 281</u>	<u>\$ 261</u>	<u>\$ 343</u>	<u>\$ 380</u>	<u>\$ 1,265</u>	<u>\$ 307</u>	<u>\$ 338</u>	<u>\$ 357</u>	<u>\$ 394</u>	<u>\$ 1,396</u>

#### Operating profit as a % of revenues

Distribution Solutions	1.49%	1.25%	1.48%	1.64%	1.47%	1.37%	1.50%	1.51%	1.76%	1.54%
Technology Solutions	11.93%	8.60%	9.92%	10.12%	10.14%	7.33%	9.90%	11.58%	8.10%	9.20%